Investigative protocols assist you with the interpretation of some common laboratory result abnormalities and the investigation of some selected clinical conditions. They are derived from a set of protocols originally produced by Dr Noel Walmsley. Some of these have now been updated, and further protocols have been added over time by Dr John Roberts.
The range of investigative protocols cover conditions associated with:
Clinical Conditions
| Abbreviation |
IP Title |
| Female |
Evaluation of ? androgen excess and/or hirsutism (female) |
| Female 1 |
Evaluation of female infertility |
| Female 2 |
Evaluation of irregular periods |
| Female 4 |
Hormonal changes during menstrual cycle |
| Prl High |
Causes of hyperprolactinaemia (prolactin >700 mIU/L) |
| Pot High |
Causes of hyperkalaemia: K+ >5.0 |
Coagulation Tests
| Abbreviation |
IP Title |
| Platelet |
Platelet function analysis (2nd stage test) |
| Thrombosis |
Risk factors for venous thromboembolism |
| vWF1 |
von Willebrand disease |
Drug Screen Interpretation
| Abbreviation |
IP Title |
| Methadone Metabolite |
Evaluation of EDDP (methadone metabolite) results |
| THC |
Evaluation of 9-tetrahydrocannabinol (THC) results |
| UDS |
Urine drug screening |
| UDS Amph |
Evalution of sympathomimetic amine results |
| UDS Barb |
Evaluation of barbiturate results |
| UDS Benzo |
Evaluation of benzodiazepine results |
| UDS Cocaine |
Evaluation of cocaine results |
| UDS Opiate |
Evaluation of opiate Results |
| UDS TLC |
Thin layer chromotography |
Endocrine Tests
| Abbreviation |
IP Title |
| Cush |
Evaluation of Cushing's syndrome |
| TSH High |
Evaluation of an elevated serum TSH (>4.0mU/L) |
| TSH Low |
Evaluation of a subnormal serum TSH (<0.2 mU/L) |
General Biochemistry
| Abbreviation |
IP Title |
| Bicarb Low |
Causes of low plasma bicarbonate (HCO3 <18) |
| Calcium High 1 |
Causes of hypercalcaemia (calcium >2.6) |
| Calcium High 2 |
Evaluation of hypercalcaemia (calcium >2.6) |
| Calcium Low |
Evaluation of hypocalcaemia (calcium <2.2) |
| CK High |
Causes of an elevated CK (M >200 F >140) |
| Globulin High |
Evaluation of hyperglobulinaemia (globulins >44) |
| Glucose Low |
Evaluation of hyperglycaemia (plasma glucose <2.8mmol/L) |
| LDI |
Evaluation of lactate dehydrogenase isoenzymes (LDI) |
| MI Change |
Cardiac enzyme changes during myocardial infarction |
| Mag Low |
Causes of hypomagnesaemia (Mg <0.7mmol/L) |
| Phos High |
Causes of hyperphosphataemia (phosphate >1.8) |
| Phos Low |
Causes of hypophosphataemia (mild 0.5~0.65 mmol/L; severe <0.4mmol/L)
|
| Polyuria |
Evaluation of polyuria (urine volume >3L/24hrs) |
| Pot High 1 |
Causes of hyperkalaemia (potassium >5.0) |
| Pot High 2 |
Evaluation of hyperkalaemia (potassium >5.0) |
| Pot Low 1 |
Causes of hypokalaemia (potassium <3.0) |
| Pot Low 2 |
Evaluation of hypokalaemia (potassium <3.0) |
| Sodium Low |
Causes of hyponatraemia (sodium <130) |
| Urate High |
Evaluation of hyperuricaemia (urate : M >0.45 F >0.40) |
Immunology
Liver Function Tests
| Abbreviation |
IP Title |
| ALP High 1 |
Causes of an isolated serum alkaline phosphatase (ALP) elevation (ALP >180IU/L) |
| ALP High 2 |
Serum alkaline phosphatase(ALP) elevation (ALP >180IU/L) |
| ALP High 3 |
Evaluation of an isolated serum alkaline phosphatase (ALP) elevation ?growth related (Age <19 y.o.) |
| ALP High 4 |
Serum alkaline phosphatase (ALP) elevation ?growth related (Age <19 y.o.) |
| ALP High 5 |
Marked Serum alkaline phosphatase (ALP) elevation (ALP >700IU/L Age <5 y.o.) |
| GGT High |
Causes of an elevated serum gamma glutamyl transferase (GGT) (GGT >100 U/L) |
| LD High |
Evaluation of an elevated serum lactate dehydrogenase (LD) (LD >300 U/L) |
| LFT 1 |
Evaluation of a moderate elevation of aminotransferase levels (AST & ALT) |
| LFT 2 |
Predominant hepatocellular pathology (ALT or AST >150U/L ALP <200 U/L) |
| LFT 3 |
Evaluation of a LFT pattern not typical of liver disease (elevated LD, AST>>ALT) |
| LFT 4 |
Causes of an isolated hyperbilirubinaemia (bili >25mmol/L, other LFT's normal) |
| LFT 5 |
Evaluation of an isolated hyperbilirubinaemia (bili >30mmol/L; other LFT"s normal) |
| LFT 6 |
Evaluation of jaundice (ALT <400U/L; ALP >350U/L) |
| LFT 7 |
Evaluation of jaundice (ALT >300U/L; ALP <350U/L) |
| LFT 8 |
Evaluation of localised cholestasis (ALP >180 U/L; ALT <150 U/L; GGT >100 U/L; Bilirubin <50 umol/L) |
| LFT 9 |
Evaluation of mixed hepatocellular and cholestatic disease (ALP >180 U/L; GGT >65 U/L; ALT or AST >150 U/L) |
Microbiology & Patient Notes
| Abbreviation |
IP Title |
| Haematuria |
Causes of isolated microscopic haematuria |
| Occult Blood |
Faecal occult blood |
| What is Barmah Forest Virus? |
Description of symptoms, treatment and prevention of Barmah Forest Virus. |
| What is Blastocystosis? |
Symptoms, infection period, diagnosis, treatment and prevention of Blastocystosis |
| What is Cryptosporidiosis? |
Symptoms, infection period, spread of infection and treatment of Cryptosporidiosis |
| What is Giardiasis? |
Symptoms, infection period, spread of infection, diagnosis, treatment and prevention of Giardiasis |
| What is Listeriosis? |
Symptoms, causes, infection period, diagnosis, treatment and prevention of Listeriosis |
| What is Parvovirus? |
Symptoms, causes, infection period, spread of infection, diagnosis, treatment and prevention of Parvovirus |
| What is Ross River Virus? |
Symptoms, infection period, spread of infection, diagnosis treatment and prevention of Ross River Virus |
Serology
| Abbreviation |
IP Title |
| Hep A |
Serological events in acute (self-limiting) Hepatitis A infection relative to Alanine Aminotransferase (ALT) peak |
| Hep B 1 |
Serological events in acute (self-limiting) Hepatitis B infection relative to Alanine Aminotransferese (ALT) peak |
| Hep B 2 |
Hepatitis B immune status |
| Pertussis |
Treatment of Bordetella Pertussis |
Warfarin Management
| Abbreviation |
IP Title |
| Warfarin 1 |
Range of International Normalised Ratio (INR) recommended for specific applications of Warfarin therapy. |
| Warfarin 2 |
Guidelines to the management of an elevated INR, with or without bleeding |
| Warfarin 3 |
Risk factors for bleeding complications of Warfarin therapy |